盐酸克林霉素棕榈酸酯分散片治疗急性扁桃体炎和急性支气管炎的成本-效果评价研究

目的 对盐酸克林霉素棕榈酸酯分散片和盐酸克林霉素片治疗急性扁桃体炎和急性支气管炎成本-效果分析，为临床合理用药提供参考。方法 采用盐酸克林霉素棕榈酸酯分散片与盐酸克林霉素片治疗急性扁桃体炎和急性支气管炎的临床观察的疗效和成本数据进行成本-效果分析。结果 盐酸克林霉素棕榈酸酯分散片组的临床痊愈率为76.47%，有效率为100%；盐酸克林霉素片组的临床痊愈率为48.98%，有效率为91.84%，盐酸克林霉素棕榈酸酯分散片组的临床痊愈率、有效率均显著高于盐酸克林霉素片组（P<0.05）。盐酸克林霉素棕榈酸酯分散片组总成本比盐酸克林霉素片组高43.09元，前者的成本-效果比（C/E）为2.27，优于后者的2.66；分别以痊愈率、有效率作为指标，前者每多获得一个百分点的痊愈率或有效率分别多花费1.57元和5.28元；分别以显效时间、痊愈时间作为指标，前者每多节省一天显效时间或痊愈时间分别多花费153.89元和307.79元。观察期间，盐酸克林霉素棕榈酸酯分散片组不良反应事件发生率为1.96%，盐酸克林霉素片组不良反应事件发生率为20.41%，经Fisher检验，组间差异具有统计学意义（P<0.05）。服药依从性（口感）评价，盐酸克林霉素棕榈酸酯分散片组口感“好”为82.35%，显著高于盐酸克林霉素片组8.16%（P<0.05）。结论 盐酸克林霉素棕榈酸酯分散片在治疗急性扁桃体炎和急性支气管炎中的临床疗效、成本-效果比、安全性和口感均优于盐酸克林霉素片。

Cost-Effectiveness analysis of Clindamycin Palmitate Hydrochloride Dispersible Tablet for the treatment of acute tonsillitis and bronchitis

Objective Cost-effectiveness analysis was performed thereafter on clindamycin palmitate hydrochloride dispersible tablet and clindamycin tablet in treating acute tonsillitis and bronchitis so as to provide a reference for the rational administration of clinical doctors. Methods Cost-effectiveness analysis of clindamycin palmitate hydrochloride dispersible tablet group and clindamycin tablet group in treating acute tonsillitis and bronchitis was performed using the data of therapeutic effect and treatment cost. Results The clinical cure rate and effective rate of clindamycin palmitate hydrochloride dispersible tablet group were significantly higher than clindamycin tablet group (76.47% vs 48.98%, P < 0.05; 100% vs 91.84%, P < 0.05). The total cost of the former was 43.09 yuan higher than the latter, and the cost-effectiveness ratio (C/E) of the former was 2.27,which was better than that of the latter, 2.66. Compared with clindamycin tablet group, as a percent of clinical cure rate and effective rate increased, the cost of clindamycin palmitate hydrochloride dispersible tablet group will increase 1.57 and 5.28 yuan; the initiating time and recovery time reduced one day, the cost will increase 153.89 and 307.79 yuan. The rate of adverse events in clindamycin palmitate hydrochloride dispersible tablet group was significantly lower than clindamycin tablet group (1.96% vs. 20.41%, Fisher test, P < 0.05). Additionally, the rate of good mouth-feel of clindamycin palmitate hydrochloride dispersible tablet group was significantly higher than clindamycin tablet group (82.35% vs. 8.16%, P < 0.05) by drug mouth-feel evaluating. Conclusion Clindamycin palmitate hydrochloride dispersible tablet has better clinical therapeutic effect, cost-effectiveness, safety and mouth-fell profile compared to clindamycin tablet in the treatment of acute tonsillitis and bronchitis.